We are certified exporters of pharmaceutical products
Finally, we outline the implications of adopting semaglutide as a disease-modifying agent in MASH with F2-F3 fibrosis, note the study limitations and remaining questions, and argue that combinatorial approaches targeting complementary metabolic and hepatocentric pathways may define the next phase of MASLD management
Tirzepatide (Mounjaro): A dual GIP/GLP-1 receptor agonist with MHRA approval for type 2 diabetes and, more recently, for weight management in adults with obesity or overweight with weight-related comorbidities
Neuropsychopharmacology, 15 , 456464
Do not use tirzepatide if you: Have a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Agency / MultiClient License Upgrade